| Outcome Measures: |
Primary: Change in radiologic liver parameters, Number of participants reported change in liver fat content from baseline, as quantified by fibroscan, 12 months | Secondary: Change in liver enzymes, Number of participants reported change in liver enzymes levels including ALT, AST and GGT, 12 months|Change in Fibrosis-4 (FIB-4) Score and NAFLD Fibrosis Score, Number of participants reported change in FIB-4 Score and NAFLD Fibrosis Score. Fibrosis-4 scores range from 0 to 4, where \<1.45 indicates absence of cirrhosis; score between 1.45 - 3.25 are deemed inconclusive and score \>3.25 indicates cirrhosis., 12 months|Change in body weight, Number of participants reported change in body weight from baseline (treat to target response of at least 5% of baseline at 6 months, 10% baseline over 12 months)., 12 months|Change in waist circumference (WC), Number of participants reported change in waist circumference (WC), 12 months|Change in liver fat mass with total body fat (TBF), Comparison of baseline and end of treatment liver fat mass with total body fat (TBF) using a Body Composition Monitor, 12 months|Change in HbA1C levels (< 7.0%), Number of participants reported change in HbA1C levels from baseline to end of treatment, 12 months|Change in Fasting Blood Sugar (FBS), Number of participants reported change in Fasting Blood Sugar (FBS) from baseline to end of treatment, 12 months|Change in Lipid profile, Number of participants reported change in Fasting triglycerides (TG), Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL) from baseline to end of treatment, 12 months | Other: Change in Urine Albumin to Creatinine Ratio (UACR), Number of participants reported change in Urine Albumin to Creatinine Ratio (UACR) from baseline to end of treatment, 12 months|Change in Systolic and Diastolic blood pressure, Number of participants reported change in Systolic and Diastolic blood pressure from baseline to end of treatment, 12 months
|
